Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA ended the third quarter with $4.33 billion revenue and non-GAAP earnings per share of $0.69, beating the analysts’ consensus, which had forecast $4.12 billion revenue and…
Teva reports seventh straight quarter of growth
by
Tags: